Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

CompletedOBSERVATIONAL
Enrollment

490

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Liver CirrhosisHepato-Renal SyndromeChronic Kidney Diseases
Interventions
DRUG

terlipressin or noradrenalin plus albumin

Patients with clinical suspicion of HRS-AKI or HRS-AKI-like syndrome in case of previously diagnosed CKD who had received vasoactive treatment for the management of HRS, as defined by the administration of terlipressin or noradrenalin plus albumin.

Trial Locations (4)

Unknown

University Medical Center Freiburg, Freiburg im Breisgau

University Medical center Jena, Jena

University Medical Center Mainz, Mainz

University Hospital Münster, Münster

All Listed Sponsors
collaborator

Jena University Hospital

OTHER

collaborator

Johannes Gutenberg University Mainz

OTHER

collaborator

University Hospital Muenster

OTHER

lead

University Hospital Freiburg

OTHER

NCT06161766 - Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease | Biotech Hunter | Biotech Hunter